INT72109

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1997
Last Reported 2009
Negated 1
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 0.80
Pain Relevance 2.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Glp1r) signal transducer activity (Glp1r)
Anatomy Link Frequency
fat 4
pylorus 2
trunks 2
Glp1r (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Somatostatin 8 100.00 Very High Very High Very High
antagonist 15 99.86 Very High Very High Very High
qutenza 6 99.42 Very High Very High Very High
Chronic pancreatitis 1 98.24 Very High Very High Very High
Potency 1 96.56 Very High Very High Very High
agonist 8 95.72 Very High Very High Very High
Clonidine 1 84.92 Quite High
vagus nerve 3 84.52 Quite High
anesthesia 4 82.88 Quite High
Intracerebroventricular 1 81.32 Quite High
Disease Link Frequency Relevance Heat
Pancreatitis 1 98.24 Very High Very High Very High
Diabetes Mellitus 8 96.88 Very High Very High Very High
Gastric Fistula 1 73.88 Quite High
Apoptosis 1 70.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Atropine (a nonspecific muscarinic receptor antagonist) completely inhibited fat-induced GLP-1 secretion in vivo (P < 0.01).
Negative_regulation (inhibited) of Localization (secretion) of GLP-1 in fat associated with antagonist
1) Confidence 0.59 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.26
Pirenzepine (an M1 muscarinic receptor antagonist) also inhibited fat-induced GLP-1 secretion in vivo, by 91 +/- 6% (P < 0.01).
Negative_regulation (inhibited) of Localization (secretion) of GLP-1 in fat associated with antagonist
2) Confidence 0.59 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.27
Pirenzepine and gallamine significantly inhibited bethanechol-stimulated GLP-1 secretion, by 96 +/- 12% and 98 +/- 8%, respectively (P < 0.01).
Negative_regulation (inhibited) of Localization (secretion) of GLP-1
3) Confidence 0.59 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.25
Acid secretion in conscious pylorus-ligated rats was inhibited by intracisternal GLP-1 administration, whereas systemic GLP-1 was ineffective.
Negative_regulation (inhibited) of Localization (secretion) of GLP-1 in pylorus
4) Confidence 0.43 Published 1997 Journal Am. J. Physiol. Section Abstract Doc Link 9357836 Disease Relevance 0.07 Pain Relevance 0.08
Capsaicin treatment on esophageal vagal trunks abolished the GLP-1 secretion induced by duodenal ZeinH but did not affect the secretion induced by jejunal or ileal ZeinH.
Negative_regulation (abolished) of Localization (secretion) of GLP-1 in trunks associated with qutenza
5) Confidence 0.43 Published 2009 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 19661152 Disease Relevance 0 Pain Relevance 0.18
Additionally, GLP-1 and PYY secretions are positively modulated by alpha1-receptor stimulation and inhibited by alpha2-receptor activation upon beta-receptor occupation.
Negative_regulation (inhibited) of Localization (secretions) of GLP-1
6) Confidence 0.42 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10425466 Disease Relevance 0 Pain Relevance 0.23
GLP-1 secretion, on the other hand, is also impaired, but its insulinotropic and glucagon-suppressive actions are preserved, although the potency of GLP-1 in this respect is decreased compared to healthy subjects.
Negative_regulation (impaired) of Localization (secretion) of GLP-1 associated with potency
7) Confidence 0.20 Published 2009 Journal Mol. Cell. Endocrinol. Section Abstract Doc Link 18786605 Disease Relevance 0.73 Pain Relevance 0.15
Simultaneous addition of receptor antagonists to all three tachykinin receptors (CP96345, SR48968, and SR142801, all at 10(-6) M) significantly inhibited the effect of capsaicin on VIP release, whereas the release of GLP-1 and somatostatin was unaffected.
Neg (unaffected) Negative_regulation (unaffected) of Localization (release) of GLP-1 associated with qutenza, antagonist and somatostatin
8) Confidence 0.09 Published 1999 Journal Dig. Dis. Sci. Section Abstract Doc Link 10489905 Disease Relevance 0 Pain Relevance 0.89

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox